UPDATE: Applera Pledges $75M to Commercialize Genomics Discoveries | GenomeWeb

NEW YORK, July 24 – Applera will spend $75 million over the next year to realize a return on its "substantial investment in sequencing the human genome,” by establishing a wide-ranging drug discovery and diagnostics development program across its three businesses, Celera Genomics, Celera Diagnostics, and Applied Biosystems, Applera CEO Tony White said Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.